Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Conference report

Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases

M. Patricia D’Souza a,⇑, Amy C. Palin a, Thomas Calder, b Hana Golding c, Steven H. Kleinstein d,e, Erin L. Milliken f, David O’Connor g, Georgia Tomaras h, Jon Warren i, Cesar Boggiano j

a Vaccine Clinical Research Branch, Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA
b Office of the Director, Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA
c Division of Viral Products, Center for Biologies Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
d Interdepartmental Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA
e Department of Pathology and Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA
f NOVA Research Company, Silver Spring, MD, USA
g Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA
h Duke Human Vaccine Institute, Duke University, Durham, NC, USA
i Pre-clinical Research and Development Branch, Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA

Article info

Article history:
Received 14 January 2021
Received in revised form 24 July 2021
Accepted 26 July 2021
Available online 6 August 2021

Keywords:
Vaccine
HIV
Tuberculosis
Influenza
SARS-CoV-2
Assay
Technology

Abstract

Modern vaccinology has experienced major conceptual and technological advances over the past 30 years. These include atomic-level structures driving immunogen design, new vaccine delivery methods, powerful adjuvants, and novel animal models. In addition, utilizing advanced assays to learn how the immune system senses a pathogen and orchestrates protective immunity has been critical in the design of effective vaccines and therapeutics. The National Institute of Allergy and Infectious Diseases of the National Institutes of Health convened a workshop in September 2020 focused on next generation assays for vaccine development (Table 1). The workshop focused on four critical pathogens: severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and human immunodeficiency virus (HIV)—which have no licensed vaccines—and tuberculosis (TB) and influenza—both of which are in critical need of improved vaccines. The goal was to share progress and lessons learned, and to identify any commonalities that can be leveraged to design vaccines and therapeutics.

1. Current landscape of clinical trials and correlates of protection

The first session of the workshop focused on clinical trials infrastructure and use of assays to identify correlates of protection in the context of trials. As the coronavirus disease 2019 (COVID-19) pandemic emerged in the United States and around the world, programs and investigators from the HIV field and other areas of immunology/virology have adapted their expertise and technologies to quickly investigate vaccines, therapeutics, and diagnostics for SARS-CoV-2. NIH brought together the resources and expertise of four existing NIH networks—the HIV Vaccine Trials Network (HVTN), Infectious Diseases Clinical Research Consortium (IDCRC), AIDS Clinical Trials Group (ACTG), and HIV Prevention Trials Network (HPTN)—to create the COVID-19 Prevention Network (CoVPN) to develop and conduct vaccine efficacy and mAb prevention trials (presented by Jim Kublin) [1,2]. The CoVPN optimized site selection and enrollment through collaboration with a predictive analytics effort—the HHS Protect Dashboard—that was launched to provide pathogen- and society-associated data and guidance to CoVPN and other federal COVID-19 efforts, including predictive modeling and early infection data (presented by Julie Ledgerwood) [3]. This approach has enabled the CoVPN to expeditiously activate more than 150 clinical trial sites in areas across the United States and internationally in epidemiological “hot spots.”

CoVPN is working with multiple vaccine developers using a variety of vaccine designs, including mRNA, plasmid, and recombinant protein approaches. Among the companies partnering with CoVPN is Janssen, which shared their early-stage results at the workshop. Janssen repurposed its adenovirus 26 platform—currently being tested for vaccines against Ebola, HIV, respiratory syncytial virus, and Zika—to include the gene for the SARS-CoV-2 spike protein (presented by Maria Grazia Pau) [4]. Ad26-based vaccine
vectors have been induced to produce a polyclonal antibody response and CD4/8 T cell responses with a Th1 signature. The US FDA granted Emergency Use Authorization to Janssen's SARS-CoV-2 vaccine in February 2021.

Once additional understanding of SARS-CoV-2 immunity, and specifically vaccine immune responses that predict protection against COVID-19 are acquired, it might be possible to accelerate approval and licensure of a COVID-19 vaccine based on a surrogate endpoint (e.g., immune response) that is reasonably likely to predict clinical benefit. The CoVPN trials are using a harmonized vaccine protocol developed by the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public–private partnership that will enable analyses of correlates of protection across multiple trials [1]. Many assays being used to measure immunological endpoints for CoVPN trials have been developed or refined by NIAID-funded investigators for HIV vaccines; these include spike protein binding antibody, neutralizing Ab (nAb) assays using live virus or pseudovirus, and T cell assays. Florian Krammer highlighted the development of an ELISA to measure serological response to SARS-CoV-2, similar to assays developed for influenza. The assay is being used to assess the correlation between serologic response and nAb in SARS-CoV-2-infected patients and determine whether a protective titer against SARS-CoV-2 can be established [5,6]. Mechanistic studies are also being used to support the case for immunologic biomarkers. The CoVPN Statistical Center is working with laboratory researchers to identify biomarkers—including binding Ab and nAb biomarkers—with broad dynamic range and limited technical measurement error with the goal of establishing correlates of protection [presented by Peter Gilbert] [7].

Having a common assay to evaluate correlates of protection allows for comparability of data across studies. For example, a clinical assay for Ebola virus vaccines (glycoprotein ELISA) was developed collaboratively through the Filovirus Animal Nonclinical Group (FANG). A single assay was validated for nonhuman primates (NHP) and human samples, which was important because Ebola vaccines may be approved under the Animal Rule. The assay was reviewed under a single Master File, which can be cross-referenced by any vaccine developer. There are similar efforts in the United States and globally to coordinate assay development for SARS-CoV-2. Moreover, if there is demonstration of protection in one population, effectiveness of the same vaccine could be inferred in other populations, such as pediatrics, by comparing immune response biomarker(s) between populations using pre-specified criteria. Provided assays are well qualified, regulators are willing to be flexible with respect to assay development and use, particularly for use with nonclinical data studies and assessments of risk-based approaches in testing and trial design [presented by Robin Levis].

These SARS-CoV-2 studies are taking advantage of decades of past research experience in other infectious diseases. Mechanisms—and correlates—of protection vary across pathogens. For example, the HIV broadly neutralizing antibody, VRC01, targets the conserved CD4 binding site of the HIV envelope [8,9] and has been demonstrated to prevent HIV infection in non-human primate (NHP) challenge studies [10]. Building on these NHP results, the first efficacy studies of VRC01—termed the Antibody Mediated Prevention (AMP) trials [11,12]—for HIV prevention were launched to determine whether a serum titer of nAb can be established as a biomarker of protection in humans (presented by John Mascola).

The internationally conducted AMP trials demonstrated protection from acquisition of HIV isolates sensitive to neutralization by VRC01, providing a proof-of-concept for prophylaxis with broadly neutralizing antibodies [13]. Future trials with improved antibodies and cocktails are planned. In addition to potentially leading to a new HIV prevention modality, evaluating the preventive efficacy of mAbs will inform future HIV immunogen design by providing an assessment of the amount of neutralizing antibody required to achieve protection [14]. In the TB field, researchers are exploring correlates of protection afforded by BCG, the only approved TB vaccine, as well as a novel polyprotein-adjuvant TB vaccine candidate. Protection induced by the BCG TB vaccine against TB disease in adolescents and adults is highly variable, and there are currently no known correlates of protection. However, recent NHP studies suggest that antigen-specific Th1 and Th17 responses and IgA antibodies in the lungs correlate with BCG-induced protection against TB [15,16]. These measures will be explored in trials testing the efficacy of BCG revaccination and a polyprotein-adjuvant TB vaccine (presented by Tom Scriba).

2. Next generation tools and technologies

Advanced technologies allow for interrogation of how the immune system responds to a vaccine, or to infection, and of the epitopes on an immunogen that elicit immune responses. To develop enhanced immunogens, researchers can use paired heavy and light chain B cell sequencing analysis to better understand clonal expansion and somatic hypermutation (SHM) for infectious agents, such as HIV (presented by Kristen Cohen) [17] and influenza (presented by Sarah Andrews) [18]. By using multiplexed fluorophore-tagged proteins, lymphocyte antigen specificity is linked to single-cell receptor sequencing. These data are applied to develop immunogens that can drive SHM and development of broadly neutralizing antibodies (bnAbs) (presented by Kristen Cohen) and to identify cross-reactive B cell receptors responding to influenza vaccination (presented by Sarah Andrews). LIBRA-Seq expands upon the use of fluorophore-tagged proteins to include oligo-tagged proteins. In principle, this technique can be
very highly multiplexed to accommodate and resolve unlimited epitopes. Using LIBRA-Seq, researchers can build high-resolution antigen specificity maps (presented by Ivelin Georgiev) [19]. Similarly, the structural techniques electron microscopy-based polyclonal epitope mapping (EMPEM) [20] and cryogenic electron microscopy (CryoEM) [21] permit very detailed mapping of epitope binding from polyclonal sera. These techniques can be applied rapidly and accommodate native antigens, providing significant advantages over traditional crystallography (presented by Gabe Ozorowski). The advancement of these approaches is enabling researchers to elucidate the structural basis of virus-antibody interactions and improve immunogens for a variety of infectious agents. However, the inability to predict lymphocyte antigen specificity from antigen receptor sequences remains a major gap.

Interrogation of the host/recipients response is another critical aspect of vaccine design. Development of activation-induced marker (AIM) assays (presented by Shane Crotty) has overcome two major technical limitations: identification of germinal center T follicular helper cells (GC Tfh), which do not produce high levels of cytokines, and identification of live, antigen-specific T cells, in contrast to cytokine detection methods that require fixation [14,22–24]. This technique has allowed more sensitive detection of T cells responding to a given antigen and can be applied to study responses in lymphoid tissue, complementing existing tools for detecting cellular immune responses that includes flow cytometry-based approaches (tetramers, intracellular cytokine staining, cytometry by time of flight (CytOF)), and tissue culture-based assays (cytotoxic target killing assays. ELSpot). In parallel, application of lymph node fine needle aspirates (FNAs) has enhanced the ability to interrogate adaptive immune responses at the anatomical sites where they occur (presented by Shane Crotty and Kristen Cohen) [25]. Recently developed techniques for single-cell analysis allow characterization of cellular heterogeneity at unprecedented resolution, as well as the unmasking of rare cell populations. Of particular relevance, advances in single-cell RNA sequencing technology, such as the Seq-Well platform, have dramatically increased utility and access by lowering cost and equipment barriers (presented by Alex Shalek) [26]. These technologies can be applied to specimens obtained in the context of human (or model system) trials to examine immune homeostasis and uncover correlates (or mechanisms) of successful or failed responses. Full sample processing on experimental medicine or subsets of samples may make the most sense however due to cost and complexity, with careful banking of samples to enable subsequent processing guided by clinical observations.

The technologies discussed above are most productively applied to early-stage clinical or pre-clinical development in order to understand mechanism and drive development of better vaccines. These rapidly evolving technologies are highly specialized, protocol specific assays to support iterative product development and not easily amenable to industry-level standards for assay validation. These approaches are better suited to exploratory endpoints, rather than primary validated or qualified assays that enable reliable quantitative assessments of immune functions and specificities across different vaccine platforms (Fig. 1).

3. Integrating data to define immune signatures of infection and vaccination responses in humans

Integration of multidimensional data using systems immunology approaches can generate signatures that characterize how, where, and when hosts fight specific pathogens or respond to vaccination, informing therapeutic and preventive strategies. As one example, researchers are integrating multi-omics data to predict systems level disease severity in COVID-19 patients. Data from mass cytometry, cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq), and ex vivo stimulation of plasmacytoid dendritic cells collectively suggest spatial and temporal dichotomies in the immune response in COVID-19. Specifically, research has found excessive proinflammatory responses in the lung, and suppressed innate immunity in the peripheral blood. Additionally, there is a low-level, transient spike in IFN-α early in disease that leads to later upregulation of IFN-stimulated genes. Differences between moderate and severe disease have been observed (presented by Bali Pulendran) [27].

Leveraging biological, clinical, and technical heterogeneity across multiple diverse datasets has been repeatedly shown to identify generalizable signatures in tuberculosiss [28] and sepsis [29]. This approach was used to identify a conserved host response to viral infections: a meta-virus signature (MVS) [29]. Its association with disease severity across multiple viruses was demonstrated using greater than 5000 samples from patients with one of 16 viral infections from 18 countries [30]. The MVS was validated using bulk RNA-seq data from 62 SARS-CoV-2 patients from Greece, and scRNA-seq of 702,000 immune cells from 289 samples across three clinical centers in the US. Further analysis showed that the MVS score is higher in myeloid cells, particularly CD14 monocytes. The number of CD14 cells increased with severity of disease, and the transcriptional profiles of these cells change. This work has led to the identification of a 5-gene signature for predicting severity of SARS-CoV-2 infection, which will be developed into a qRFLAMP-based assay for point-of-care test (presented by Purvesh Khatri) [31].

Systems immunology also can be used to characterize responses to infection and vaccination and inform iterative improvements in vaccine design. In the field of HIV research, data from high-dimensional assays for viral and host factors, global antibody repertoire, cellular immune environment, and transcription were integrated to define signatures of the immunological environment permissive to generation of HIV-1 bnAbs (presented by Isabela Pedroza-Pacheco). Correlation network analysis suggested that hyper-immune activation and activation of CD4 T cells plays important roles. These results suggest that vaccines should be designed to elicit high-magnitude, functionally potent CD4 Tfh responses that are targeted to provide help to bnAb-producing B cell lineages while limiting activation of regulatory cells.

Systems immunology is also accelerating adjuvant design. CITE-seq has been used to look at the molecular and cellular underpinnings of a previously identified 10-gene signature associated with influenza and yellow fever vaccine responses (presented by John Tsang). Results suggest that high responders have more activated plasmacytoid dendritic cells, elevated type I IFN signaling, and more persistently activated T and B cells at baseline [32]. This “naturally adjuvanted state” enables a stronger plasmablast response to vaccination or other triggers. Increased understanding of the natural adjuvanted state may guide development of engineered adjuvants.

Systems immunology can be facilitated by centralized data repositories and analysis tools. ImmuneSpace (https://www.immunespace.org) is an example of a data management and analysis engine that was created to facilitate research on data from the Human Immunology Project Consortium (HIPC) using cutting-edge computational tools. The goal of this resource is to characterize the status of the immune system in diverse populations under both normal conditions and in response to stimuli (presented by Raphael Gottardo) [33]. The Immune Epitope Database (IEDB http://www.iedb.org/) is another systems tool that houses experimentally derived epitope information from the published literature and direct submissions, primarily NIAID Epitope Discovery contracts. IEDB features a sophisticated search interface, as well
4. Developing and translating immune and protection correlates in Non-Human primate models

The last session covered the use of NHP models to conduct immune correlate studies that are difficult or impossible to do in humans, such as investigating immunological features associated with protection imparted by SIV vaccines. A study of whole-blood transcriptome profiling of rhesus macaques that received a 68–1 RhCMV/SIV vaccine identified a protective gene expression signature involving IL-15. This signature was significantly higher in nonprotected animals at baseline. Vaccinated macaques that were protected from SIV challenge tended to have a more quiescent IL-15 signaling pathway at baseline and manifested post-vaccination enhancement of IL-15 signaling (presented by Michael Gale). Maintenance of the protective profile was essential for protection from disease. Differences were driven mainly by monocytes, with contributions from T cells and NK cells. These data suggest that IL-15 response could be a pivotal factor in programming RhCMV/SIV vaccine-induced immune protection [35].

In another SIV study, a variety of assays—including conventional immunoassays and assays measuring transcriptomes, extracellular vesicle mRNAs, and the epigenome—were used to assess correlates of risk and protection in the SIVmac251 model (presented by Genoveffa Franchini; Bissa et al. in preparation) [36–39]. Collectively, these data suggest roles for anti-inflammatory macrophages, NK cells, Th1 cells, antibodies to V2, and Treg cells in vaccine-mediated protection from mucosal infection. Results from multiple assays pointed to differences in regulation of CREB signaling being associated with protection. This is consistent with human data from RV144 showing a trend towards higher levels of CREB1-driven genes in protected patients (Sekaly, R under revision, Nature Immunology).

To explore bnAb development, researchers used clinically relevant simian-human immunodeficiency virus (SHIV) challenge stocks to study bnAb generation in rhesus macaques (presented by George Shaw) [14]. The bnAbs elicited in macaques target mul-
multiple epitopes and closely resemble HIV-1 bnAbs. The presence of bnAbs in vivo elicited escape through mutation of residues 166 and 169, suggesting these residues are sufficient for driving affinity maturation leading to bnAb breadth and potency. These findings validate the rhesus model for HIV-1 vaccine research. In particular, analysis of Env-Ab coevolution leading to neutralization breadth in SHIV-infected macaques could help guide HIV-1 vaccine design and testing [40].

NHPs also have been used to evaluate attenuated dengue strains for vaccination and use in controlled human infection models (CHIMs; presented by Anna Durbin) [41]. Based on NHP data, two strains developed from the DENV-2 Tonga/74 virus—DEN2Δ30 and DEN3Δ30—were evaluated as challenge strains. In a human challenge study, all human subjects developed viremia and the vast majority developed dengue rash when exposed to the challenge strains, but none developed signs of serious infection. Two candidate dengue vaccines—TV003 and TV005—were found to completely protect against viremia induced by the DENV2 challenge strain in early-phase trials [42]. TV003 currently is being evaluated in a phase 3 trial. Efficacy results should be available in about one year.

These examples illustrate the value of using NHPs to explore vaccine-induced protective (and non-protective) signatures or biomarkers in advancing product development without costly human trials. Systems analyses in NHP models are able to interrogate the timing of these signatures, and to allow collection of invasive tissue specimens which are typically not possible in human studies.

5. Key themes and next steps

Several key themes emerged from workshop presentations and discussion. The rapid planning and launch of SARS-CoV-2 clinical trials and the surge of knowledge about SARS-CoV-2 and COVID-19 illustrate the value of investment in clinical and research infrastructure for infectious disease research at a global level. Following direct demonstration of protection in one population, effectiveness of the same vaccine could be inferred in other hard to recruit pop-
ulations by immunobridging, using validated immunological assays and by comparison of immune response biomarker(s) between populations using pre-specified criteria. These immune assays can serve to predict clinical benefit as well as effectiveness as immune vanities over time. Merging cutting-edge technologies provides unprecedented opportunity to learn more about immune responses at the systems level (Fig. 2). However, this work can present technical challenges, as the high-throughtput data requires extensive computational mining to generate novel hypotheses that can guide further investigational product design. These omics-based technologies often require expensive equipment and technical knowledge that are not readily transferrable between development groups. Because of its complexity, this work will require targeted funding and fostering of collaborations to promote optimal application of these technologies across pathogens. Investments in technological improvements are needed to move toward validation of these assays and tools and large-scale use, including in the context of clinical trials. Existing data should be leveraged to the extent possible, including use of centralized data repositories and analysis resources. New studies should be thoughtfully designed to ensure that informative samples are available to address a range of high-value research questions now and in the future (Table 2). And to address the substantial analytical challenges associated with large, multimodal datasets, efforts should be made to increase bioinformatics expertise within the immunology and vaccine development fields. Investments in these areas, and the support of a diverse biomedical workforce, will create the learning environment required to conduct effective and cutting-edge translational research globally and ensure a pipeline of highly-skilled investigators poised to advance the next generation of vaccines and therapeutics.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The workshop “Next generation of Assays, Tools, Technologies to Evaluate Immune Responses to Vaccines for Infectious Diseases” was organized and funded by the National Institute of Allergy and Infectious Diseases, Division of AIDS, Vaccine Research Program. The authors are grateful to Rose Perry, Ryan Kissinger, and Anita Mora of the Visual and Medical Arts Unit, Research Tenchnologies Branch of NIAID for their work in realizing the figures included in this manuscript.

References

[1] Corey L, Mascola JR, Fauci AS, Collins FS. Science 2020;368(6494):948–50.
[2] COVID-19 Prevention Network, Home page, https://covid19.preventionnetwork.org/ (Accessed 2020 Nov 13).
[3] Johns Hopkins University & Medicine, Coronavirus Resource Center: testing trends tool, https://coronavirus.jhu.edu/testing/ (Accessed 2020 Nov 13).
[4] Barouch DH, Tomaras GD, Margolick JB, Zhang Z, Amin S, Gao F, et al. Science 2020;369(6508):1210–20.
[5] Butler A, Briney T, Carnathan DG, Torrents de la Pena A, Pauthner M, Briney T, et al. Cell Rep 2016;17(9):2195–209.
[6] Hansell SM, Heppleston AG, Tovey AC, Melville D, Whyte R, et al. Lancet Respir Med 2016;4(8):288–300.e8.
[7] Wang J, Stanford C, Farquer R, Li Y, Zhang Y, et al. Cell 2019;179(7):1636–1646.e15.
[8] Mora of the Visual and Medical Arts Unit, Research Tenchnologies Branch of NIAID for their work in realizing the figures included in this manuscript.

Arinsburg S, Bandres JC, Siddiquie MN, Schilke RM, Woolard MD, Zhang H, Dutty AJ, Kraus TA, Moran TM, Tortorella D, Lim JK, Garsnik AV, Hioe CE, Zolla-Pazner S, Ivanov SK, Karnjit JP, Krammer F, Lee B. Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera. medRxiv 2020. p. 2020.08.13.20157222.
[9] Mehrotra DV, James HE, Fleming TR, Annunziata PW, Neuzil KM, Carpp LN, et al. Ann Intern Med 2020.
[10] Caskey M, Klein F, Nussenzweig MC. Nat Med 2019;25(4):547–53.
[11] Migliorati CA, Migliorati EK, Silverman Jr S, Greenspan D, Greenspan JS. J Oral Pathol 1986;15(6):352–8.
[12] Nishimura Y, Martin MA. Cell Host Microbe 2017;22(2):207–16.
[13] Clinicaltrials.gov, Evaluating the safety and efficacy of the VRC01 antibody in reducing acquisition of HIV-1 infection in women, 2015 Oct 15. https://clinicaltrials.gov/show/NCT02565215. (Accessed 2020 Nov 13).
[14] Clinicaltrials.gov, Evaluating the safety and efficacy of the VRC01 antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men, 2016 Mar 23. https://clinicaltrials.gov/c2/show/NCT02271657. (Accessed 2020 Nov 13).
[15] Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, Edupuganti S, et al. Lancet Respir Med 2016;4(3):233–43.
[16] Havenar-Daughton C, Carnathan DG, Torrents de la Pena A, Pauthner M, Briney T, et al. Cell Rep 2016;17(9):2195–209.
[17] Tovar DA, Giel HS, Wadsworth 2nd MH, Hughes TK, et al. Nature 2020;577(7788):16–25.
[18] Huang D, Abbott RK, Havenar-Daughton C, Skog PD, Al-Kolla R, Groschel B, Migliorati CA, Migliorati EK, Silverman Jr S, Greenspan D, Greenspan JS. J Oral Pathol 1986;15(6):352–8.
[19] Mehrotra DV, Janes HE, Fleming TR, Annunziata PW, Neuzil KM, Carpp LN, et al. Ann Intern Med 2020.
[20] Caskey M, Klein F, Nussenzweig MC. Nat Med 2019;25(4):547–53.
[21] Migliorati CA, Migliorati EK, Silverman Jr S, Greenspan D, Greenspan JS. J Oral Pathol 1986;15(6):352–8.
[22] Nishimura Y, Martin MA. Cell Host Microbe 2017;22(2):207–16.
[23] Clinicaltrials.gov, Evaluating the safety and efficacy of the VRC01 antibody in reducing acquisition of HIV-1 infection in women, 2015 Oct 15. https://clinicaltrials.gov/show/NCT02565215. (Accessed 2020 Nov 13).
[24] Clinicaltrials.gov, Evaluating the safety and efficacy of the VRC01 antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men, 2016 Mar 23. https://clinicaltrials.gov/c2/show/NCT02271657. (Accessed 2020 Nov 13).
[25] Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, Edupuganti S, et al. Lancet Respir Med 2016;4(3):233–43.
[26] Havenar-Daughton C, Carnathan DG, Torrents de la Pena A, Pauthner M, Briney T, et al. Cell Rep 2016;17(9):2195–209.
[27] Tovar DA, Giel HS, Wadsworth 2nd MH, Hughes TK, et al. Nature 2020;577(7788):16–25.
[28] Huang D, Abbott RK, Havenar-Daughton C, Skog PD, Al-Kolla R, Groschel B, Migliorati CA, Migliorati EK, Silverman Jr S, Greenspan D, Greenspan JS. J Oral Pathol 1986;15(6):352–8.
[29] Mehrotra DV, Janes HE, Fleming TR, Annunziata PW, Neuzil KM, Carpp LN, et al. Ann Intern Med 2020.
[30] Caskey M, Klein F, Nussenzweig MC. Nat Med 2019;25(4):547–53.
[31] Migliorati CA, Migliorati EK, Silverman Jr S, Greenspan D, Greenspan JS. J Oral Pathol 1986;15(6):352–8.
[32] Nishimura Y, Martin MA. Cell Host Microbe 2017;22(2):207–16.
[33] Clinicaltrials.gov, Evaluating the safety and efficacy of the VRC01 antibody in reducing acquisition of HIV-1 infection in women, 2015 Oct 15. https://clinicaltrials.gov/show/NCT02565215. (Accessed 2020 Nov 13).
[34] Clinicaltrials.gov, Evaluating the safety and efficacy of the VRC01 antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men, 2016 Mar 23. https://clinicaltrials.gov/c2/show/NCT02271657. (Accessed 2020 Nov 13).
[35] Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, Edupuganti S, et al. Lancet Respir Med 2016;4(3):233–43.
[36] Havenar-Daughton C, Carnathan DG, Torrents de la Pena A, Pauthner M, Briney T, et al. Cell Rep 2016;17(9):2195–209.
[37] Tovar DA, Giel HS, Wadsworth 2nd MH, Hughes TK, et al. Nature 2020;577(7788):16–25.
[38] Huang D, Abbott RK, Havenar-Daughton C, Skog PD, Al-Kolla R, Groschel B, Migliorati CA, Migliorati EK, Silverman Jr S, Greenspan D, Greenspan JS. J Oral Pathol 1986;15(6):352–8.
[39] Mehrotra DV, Janes HE, Fleming TR, Annunziata PW, Neuzil KM, Carpp LN, et al. Ann Intern Med 2020.
[40] Caskey M, Klein F, Nussenzweig MC. Nat Med 2019;25(4):547–53.
[41] Migliorati CA, Migliorati EK, Silverman Jr S, Greenspan D, Greenspan JS. J Oral Pathol 1986;15(6):352–8.
[42] Nishimura Y, Martin MA. Cell Host Microbe 2017;22(2):207–16.
Schifanella L, Vaccari M, Galli V, Doster MN, Liyanage NPM, Sarkis S, Caccuri F, LaBranche C, Montefiori DC, Tomaras GD, Shen X, Rosati M, Felber BK, Pavlakis GN, Venzon DJ, Magnanelli W, Breed M, Kramer J, Keefe BF, Eller MA, Cicala C, Arthos J, Ferrari G, Margolis L, Robert-Guroff M, Kwong PD, Roederer M, Rao M, Cardozo Tj, Franchini G. iScience 2021;24(2).

[37] Schifanella L, Barnett SW, Bissa M, Galli V, Doster MN, Vaccari M, et al. PLoS Pathog 2019;15(12):e1008121.

[38] Gorini G, Fourati S, Vaccari M, Rahman MA, Gordon SN, Brown DR, et al. PLoS Pathog 2020;16(3):e1008377.

[39] Silva de Castro I, Gordon SN, Liu J, Bissa M, McKinnon K, Trinh HV, et al. J Virol 2020:94.6.

[40] Roark RS, Li H, Williams WB, Chug H, Mason RD, Gorman J, Wang S, Lee F-H, Rando J, Bonsignori M, Hwang K-K, Saunders KO, Wiehe K, Moody MA, Hraber PT, Wagh K, Giorgi EE, Russell RM, Bibollet-Ruche F, Liu W, Connell J, Smith AG, DeVoto J, Murphy A, Smith J, Ding W, Zhao C, Chohan N, Okumura M, Rosario C, Ding Y, Lindemuth E, Bauer AM, Bar KJ, Ambrozak D, Chao CW, Chuang G-Y, Gong H, Liu BC, Louder MK, Nguyen R, Zhang B, Lewis MG, Raymond D, Doria-Rose NA, Schramm CA, Douek DC, Roederer M, Kepler TB, Kelsoe G, Mascola JR, Kwong PD, Korber BT, Harrison SC, Haynes BF, Hahn BH, Shaw GM. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. BioRxiv 2020. p. 2020.08.05.237693.

[41] Chan KW, Watanabe S, Kavishna R, Alonso S, Vasudevan SG. Antiviral Res 2015;123:5–14.

[42] Larsen CP, Whitehead SS, Durbin AP. Vaccine 2015;33(50):7075–82.